Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Breast Cancer Female, Met...
Phase PHASE2
Enrollment 58
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Datopotamab Deruxtecan — Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.

Primary Outcomes

  • Objective Response Rate (ORR) in RANO-BM Criteria (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-01-08
Completion: 2029-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nancy Lin, MD
Collaborators: Daiichi Sankyo
Principal Investigators:
  • Nancy Lin, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Nancy Lin, MD
6176322335
Nancy_Lin@dfci.harvard.edu
Manmeet Ahluwalia, MD
786-527-8010
manmeeta@baptisthealth.net
Miami Baptist Cancer Institute/
Manmeet Ahluwalia, MD
Miami Baptist Cancer Institute/
Interventions
  • Drug: Datopotamab Deruxtecan — Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
Study Locations (3 sites)
Miami Baptist Cancer Institute/, Miami, Florida 33176 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Duke University Medical Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria : * Metastatic breast cancer that is pathologically confirmed to be HER2-negative according to 2018 ASCO/CAP guidelines 55. * Radiological confirmation of metastatic disease. * Cohorts A and B: Presence of newly diagnosed brain metastases or brain metastases progressing after prior local and/or systemic therapy. * Cohorts A and B: Participants must have a baseline MRI of the brain performed with and without gadolinium contrast, and must have central nervous system metastases with at least one measurable brain metastasis ≥ 1.0 cm in size (per RANO-BM) that has not been irradiated, or has progressed despite prior radiation therapy and/or systemic therapy (in the opinion of the treating physician). For cohorts A and B, head CT with contrast may be used in place of MRI at baseline and throughout the trial if MRI is contraindicated and the participant's CNS metastases are clearly measurable by head CT. * Cohorts C: Radiological evidence of evaluable leptomeningeal disease and clinical diagnosis of LMD per treating investigator. A positive CSF cytology is not required. * Cohort A: prior progression to treatment with at least one line of endocrine treatment (with or without CDK4/6 inhibition) in the metastatic setting is mandatory. Patients experiencing recurrence during adjuvant endocrine treatment will be also considered eligible for the trial. There is no limit on the number of prior lines acceptable for the purpose of enrollment in this study. * Cohort B and C: no prior treatment is required (i.e., previously untreated patients are eligible). There is no limit on the number of prior lines of therapy acceptable for the purpose of enrollment in this study. * Participants may have measurable or non-measurable extracranial disease. Participants are NOT required to have extracranial disease, but must have imaging done to document disease status at baseline. * Age ≥ 18 years. * ECOG Performance Status 0-2 * Participants must have adequate treatment washout period before registration, defined as \> 4 weeks from major surgery, \> 2 weeks from radiation treatment. For weekly chemotherapy regimens, \> 2 weeks from chemotherapy; for every 3 weekly regimens, \> 3 weeks from chemotherapy. At least 2 weeks from other systemic or targeted or investigational therapies (other than endocrine therapy) for breast cancer. No washout is required for endocrine therapy (e.g. aromatase inhibitors, tamoxifen, fulvestrant) but patients should discontinue prior to start of protocol therapy. Patients on ovarian suppression are allowed (but not required) to continue ovarian suppression at the discretion of their treating provider. * Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. * Adequate organ function as defined by the following values: * Hemoglobin ≥ 9.0 g/dL. Red blood cell/plasma transfusion is not permitted within 1 week prior to screening assessment. * Absolute neutrophil count ≥1,500/mm3. Granulocyte colony-stimulating factor administration is not permitted within 1 week prior to screening assessment. * Platelets ≥100,000/mm3. Platelet transfusion is not permitted within 1 week prior to screening assessment. * Total bilirubin ≤ 1.5 institutional ULN if no liver metastases; or ≤ 3 x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN OR ≤ 5.0 x institutional ULN for patients with documented liver metastases * Serum creatinine ≤ 1.5 mg/dL (or glomerular filtration rate ≥ 30 ml/min as determined by the Cockcroft-Gault equation) * Participants with a history of chronic viral conditions such as HIV, Hepatitis B/C, should not be systemically excluded but have thoughtful consideration of inclusion, unless safety is a concern. Testing for these conditions is not required at baseline. * Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 14 days of initiating protocol therapy. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Visceral crisis or impending visceral crisis * CNS complications for whom urgent neurosurgical intervention is indicated (i.e., resection, shunt placement) * Indication for immediate local therapy to CNS lesion(s) as defined by local standard * Evidence of significant (i.e., symptomatic) intracranial hemorrhage -\> 2 seizures within 4 weeks prior to study entry (registration) * Ongoing/persistent toxicities caused by previous anti-cancer therapy (except alopecia) not yet improved to Grade ≤ 1 OR baseline prior to study entry (registration) * Known contraindication to MRI (e.g., due to pacemaker, ferromagnetic implants, claustrophobia, extreme obesity, hypersensitivity). However, for cohorts A and B, head CT with contrast may be used in place of MRI at baseline and throughout the trial if MRI is contraindicated and the participant's CNS metastases are clearly measurable by head CT. * Concurrent administration of other anti-cancer therapy during the course of this study is not allowed. Concurrent use of supportive care medications is allowed, and certain medications are required (see Section 5.1). * Uncontrolled intercurrent illness, including (but not limited to) active infection, severely compromised pulmonary function, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ischemic heart disease, myocardial infarction within the previous six months, gastric or duodenal ulceration diagnosed within the previous six months, chronic liver or renal disease, or severe malnutrition. Note that if a patient has controlled diabetes mellitus, but is unable to monitor blood glucose at home, they will be excluded from the trial. * Participants must not have a condition requiring ongoing systemic treatment with corticosteroids (\>4 mg daily dexamethasone (or bioequivalent)) or other immunosuppressive medications within 7 days prior to the baseline MRI. Corticosteroids administration must be stable and planned to remain ≤ 4 mg daily for the duration of protocol treatment. However, use of corticosteroids for clinical symptoms is allowed based upon treating physician discretion. * History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * A history of uncontrolled seizures, CNS disorders, or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs. * A history of malignancy other than breast cancer, except (a) adequately resected non-melanoma skin cancer, (b) curatively treated in situ disease, or (c) other solid tumors curatively treated, with no evidence of disease for ≥ 3 years. * Major surgery, open biopsy, or significant traumatic injury within 28 days prior to the initiation of protocol therapy, or anticipation of need for a major surgical procedure during the study. * Clinically significant corneal disease. * Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of datopotamab deruxtecan. * History of severe hypersensitivity reactions to other monoclonal antibodies * Negative pregnancy test (urine and/or serum) is required for women of childbearing potential. Pregnant or lactating women are excluded from participation due to potential teratogenic effects of study drug. * Female participants must be either: * post-menopausal for at least 1 year * surgically sterile, or * if of childbearing potential and sexually active with a non-sterilized male partner, must agree to use one highly effective form of birth control for the entire treatment period and for at least 7 months after the last dose of datopotamab deruxtecan (see Section 5.4 for
Conditions Emotion Regulation, Depression, Anxiety,...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Youth in Canada are in need of novel, innovative approaches to support their mental health and wellbeing. Within this age group, research suggests rates of several mental health difficulties and related hospitalizations have increased over recent decades. These challenges are exacerbated in rural communities, such as in Northwestern Ontario, where youth access mental health services less frequently and face longer wait times than those in more urban areas. Such limited access and extended waits can exacerbate symptoms, prolong distress, and increase the risk for adverse outcomes. In partnership with St. Joseph Care Group and Thunder Bay Counselling Centre, the investigators are evaluating the impact of a mental health app (JoyPop) as a tool for youth waiting for mental health services. The JoyPop app was developed to support improved emotion regulation - a fundamental difficulty for youth presenting with mental health challenges and an ability still undergoing maturation during this developmental period. A two-arm randomized controlled trial (RCT) will be used to evaluate the effectiveness of the app compared to usual practice while youth aged 12-17 are waiting for mental health services.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Usual Practice + JoyPop — Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.

Primary Outcomes

  • Change in emotion regulation (overall) (Time Frame: Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (strategies) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (non-acceptance) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (impulse) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (goals) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (awareness) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
  • Change in emotion regulation (clarity) (Difficulties in Emotion Regulation Scale - Short Form will be administered at baseline (pre), after 2 weeks (mid), and after 4 weeks (post))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2025-12
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lakehead University
Contact Information
Study Contact:
Aislin R Mushquash, Ph.D.
807-343-8010
aislin.mushquash@lakeheadu.ca
Aislin R Mushquash, Ph.D.
Lakehead University
Elaine Toombs, PhD
Lakehead University
Interventions
  • Behavioral: Usual Practice + JoyPop — Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study Locations (1 sites)
Lakehead University, Thunder Bay, Ontario P7B5E1 Canada
Eligibility Criteria
Inclusion Criteria: * Youth must be on the wait-list for mental health services at St. Joseph's Care Group or Thunder Bay Counselling Centre and be between 12-17 years old. * Eligible youth will also need to be available to attend a virtual or in-person orientation session. * In order to download the JoyPop app, participants will need access to an iOS device (e.g., iPhone, iPad). Refurbished iPhones containing just the JoyPop app will be provided to participants to use for the duration of the trial if they do not have access to their own.
Conditions Lymphedema, Lymphedema Arm, Lymphedema o...
Phase PHASE3
Enrollment 285
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Procedure: Immediate Lymphatic Reconstruction — Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
  • Diagnostic Test: Volumetric arm measurements — Volumetric arm measurements will occur at each in-person postoperative visit time points.
  • Other: Lymphatic massage — Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
  • Other: Range of motion exercises — Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
  • Other: Compression garment use — Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed

Primary Outcomes

  • The difference between the baseline and postoperative arm volume measurement (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-11-16
Completion: 2030-03-16
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 285 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Michelle Coriddi, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Michelle Coriddi, MD
646-608-8042
coriddim@mskcc.org
Babak Mahrara, MD
646-608-8085
mehrarab@MSKCC.ORG
Michelle Coriddi, MD
646-608-8042
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Procedure: Immediate Lymphatic Reconstruction — Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
  • Diagnostic Test: Volumetric arm measurements — Volumetric arm measurements will occur at each in-person postoperative visit time points.
  • Other: Lymphatic massage — Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
  • Other: Range of motion exercises — Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
  • Other: Compression garment use — Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Female sex * Diagnosis of breast cancer * Ages 18 to 75 years * Consented for unilateral ALND or for unilateral SLNB with possible ALND Exclusion Criteria: * Male sex * Does not speak English * Does not fit into study garment * Axillary recurrence * History of ALND * Requirement of bilateral ALND for the treatment of breast cancer * Treatment with SLNB only * Known anaphylactic allergy to ICG dye used in ILR * Impaired decision-making capacity
Conditions Preeclampsia
Phase EARLY_PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Aspirin — 162mg aspirin capsule
  • Drug: Placebo — placebo capsule

Primary Outcomes

  • magnitude of microvascular endothelial function (baseline, 12 weeks)
  • magnitude of brachial artery endothelial function (baseline, 12 weeks)
  • magnitude of microvascular endothelin-1 mediated constriction (baseline, 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anna Stanhewicz, PhD
Contact Information
Study Contact:
Anna Reid-Stanhewicz, PHD
319-467-1732
anna-stanhewicz@uiowa.edu
Anna Stanhewicz
319-467-1732
anna-stanhewicz@uiowa.edu
University of Iowa
Interventions
  • Drug: Aspirin — 162mg aspirin capsule
  • Drug: Placebo — placebo capsule
Study Locations (1 sites)
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion Criteria: * had preeclampsia in the past 5 years, * 18 years or older Exclusion criteria: * current daily aspirin use, * skin diseases, * current tobacco or nicotine use (including vaping), * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * currently pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs, * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Conditions Depression, Postpartum, Anxiety State
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression and anxiety are significant public health issues during pregnancy and the postnatal period, particularly affecting those in developing countries. Disruptions in biological rhythms, sleep problems, and low exposure to daylight are associated with a higher risk of these mental health issues. The perinatal period poses unique challenges to the temporal program, with evidence indicating that sleep disturbances significantly increase the risk of postnatal depression. A Randomised Clinical Trial (RCT) is being conducted to assess the effectiveness of Blue Light Therapy (BlueLT) in treating depressive and anxiety symptoms during the postpartum. The RCT will also investigate the alignment of rest-activity and internal body time as mediating factors. This study will focus on various chronobiological factors, including rest-activity rhythms, light exposure levels, temperature rhythms, sleep duration and phase, social jetlag, and BodyTime (assessed through a single blood sample). The goal is to recruit 50 women with postpartum depression, with 25 in the BlueLT intervention group and 25 in the ControlLT placebo group, alongside 100 healthy controls. The BlueLT device uses a short-wavelength LED lamp mainly composed by a wavelength peak on blue spectrum, while the ControlLT device has a dim long-wavelength LED. A Healthy Control group will also be included to account for changes unrelated to depression diagnosis or placebo/treatment effects. Exclusion criteria involve a history of major depressive or anxiety disorder, current psychotic disorder, night shift work, active suicidal thoughts, unstable medical conditions interfering with data collection, and newborns with severe health conditions. The study aims to evaluate the impact of BlueLT on postpartum depression and understand the role of chronobiological factors in the health/disease process.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Blue Light Therapy — The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
  • Device: ControlLT — The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.

Primary Outcomes

  • Depressive symptoms (From enrollment to the end of treatment at 4 weeks)
  • Anxiety symptoms (From enrollment to the end of treatment at 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-04
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Clinicas de Porto Alegre
Collaborators: Federal University of Rio Grande do Sul
Principal Investigators:
  • Maria Paz L Hidalgo (PRINCIPAL_INVESTIGATOR) - +555133596339
Contact Information
Study Contact:
Maria Paz L Hidalgo
+555133596339
mhidalgo@hcpa.edu.br
Guilherme R Amando
+555133596339
gamando@hcpa.edu.br
Maria Paz L Hidalgo
5533596339
mhidalgo@hcpa.edu.br
Hospital de Clínicas de Porto Alegre
Interventions
  • Device: Blue Light Therapy — The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
  • Device: ControlLT — The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
Study Locations (1 sites)
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul 90410-000 Brazil
Eligibility Criteria
Inclusion Criteria: * 4-6 weeks postpartum; * Postnatal depression confirmed through Edinburgh Postnatal Depression Scale (EPDS) \&amp;gt; 10; * Mini-International Neuropsychiatric Interview (M.I.N.I.) positive for current depressive episode. Exclusion Criteria: * Active suicidal ideation; * Psychotic symptoms; * Unstable general medical conditions that interfere with the acquisition of actigraphy; * Newborn with severe health conditions (hospitalization, care in the neonatal ICU).
Conditions Advanced Solid Tumor, Melanoma, Head and...
Phase PHASE2
Enrollment 740
Locations 91 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HER3-DXd — Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle

Primary Outcomes

  • Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) (Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months)
  • Proportion of Participants Achieving a ≥50% Decrease in PSA (Prostate Cancer Cohort Only) (Baseline, each cycle before infusion (each cycle is 21 days), and end of treatment, up to approximately 27 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-02-26
Completion: 2028-10-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 740 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Global Clinical Leader (STUDY_DIRECTOR) - Daiichi Sankyo
Contact Information
Study Contact:
Daiichi Sankyo Contact for Clinical Trial Information
9089926400
CTRinfo@dsi.com
See Central Contact
National Cancer Center Hospital East
See Central Contact
NHO Shikoku Cancer Center
Interventions
  • Drug: HER3-DXd — Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
Study Locations (91 sites)
City of Hope, Duarte, California 91010 United States
Yale Cancer Center, New Haven, Connecticut 06510 United States
AdventHealth Medical Group Oncology Research at Celebration, Kissimmee, Florida 34747 United States
University of Illinois Cancer Center, Chicago, Illinois 60612 United States
Johns Hopkins University, Baltimore, Maryland 21205 United States
Health Partners Frauenshuh Cancer Center, Saint Louis Park, Minnesota 55426 United States
Health Partners Cancer Center at Regions Hospital, Saint Paul, Minnesota 55101 United States
Washington University, School of Medicine, St Louis, Missouri 63110 United States
Roswell Park Cancer Institute IDS, Buffalo, New York 14203 United States
Memorial Sloan Kettering Hospital, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria Participants must meet all of the following criteria to be eligible for enrollment into the study: 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement. 2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old). 3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows: Cutaneous (acral and non-acral) melanoma 1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma 2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \[ICIs\] \[ie, anti-CTLA4, anti- LAG-3\] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF/MEK inhibitor therapy as well. Squamous cell carcinomas of the head and neck 3. Squamous cell carcinoma of the head and neck (with a primary location of oral cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive or negative (as determined by local standard). Excludes tumor location in the nasopharynx, nasal cavity, paranasal sinuses, and unknown primary locations. 4. Disease progression after having received treatment with ≥1 and \<3 prior lines of systemic therapy in the unresectable recurrent or metastatic setting. Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination with chemotherapy or other therapies). Must also have had disease progression on a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic setting or in the locally advanced setting with curative intent. Gastric or GEJ adenocarcinoma 5. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry \[IHC\] 0/1+ or IHC 2+/in situ hybridization negative) as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations. 6. Disease progression after having received treatment with ≥2 prior lines of therapy that include PBC with or without anti-PD-1 therapy. Ovarian Carcinoma 7. Pathologically documented high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. 8. Documented disease progression ≥4 weeks after the last dose of PBC and \<6 months of last dose of PBC in the advanced or metastatic setting. Prior use of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab soravtansine) is allowed. Cervical Cancer 9. Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix. 10. Disease progression after having received ≥1 line of systemic therapy in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment and/or tissue factor directed ADC (tisotumab vedotin \[TV\]) per regional standard of care. Endometrial Cancer 11. Pathologically or cytologically documented endometrial cancer (carcinoma of any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite instability (MSI) or mismatch repair (MMR) status. 12. Documented disease progression after having received ≥1 prior line of therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing regimen (combined or sequential) in the advanced/metastatic setting. Bladder Cancer 13. Pathologically or cytologically documented locally advanced/unresectable or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology. 14. Relapsed or progressed after treatment with ≥1 prior line of therapy (maximum of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor treatment for those who are eligible are allowed. * Required treatments can be given in combination or sequentially * Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy * The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy * Participants in the second-line setting who have previously received enfortumab vedotin and pembrolizumab in combination can be enrolled. Esophageal Carcinoma 15. Pathologically or cytologically documented esophageal squamous cell carcinoma. 16. Must have documented disease progression after having received 2 prior lines of therapy including previous PBC with or without an anti-PD-1 therapy-containing regimen (combined or sequential) in the advanced/metastatic setting. Pancreatic Carcinoma 17. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma. 18. Relapsed or disease progression after having received 1 prior line of systemic therapy in the locally advanced/metastatic setting. Prostate Cancer 19. Pathologically or cytologically documented unresectable locally advanced or metastatic castration-resistant prostate cancer (CRPC). 20. Adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology. 21. Surgically or medically castrated, with testosterone levels of \<50 ng/dL. 22. Documented objective progression as determined by radiographic progression for subjects with measurable disease after androgen deprivation. 23. Relapsed or disease progression after having received treatment with ≥1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide, or darolutamide. 24. Relapsed or disease progression after having received ≥1 cytotoxic chemotherapy regimen that included a taxane. Gastric Cancer 2L 25. Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression (IHC 0/1+ or IHC 2+/in situ hybridization negative) as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations. 26. Disease progression after having received treatment with only 1 prior line of systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive, treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line setting is allowed. Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement, BRAF V600E mutation, EGFR-activating mutations \[exon 19 deletion or L858R mutation\], EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14 skip
Conditions Breast Carcinoma
Phase PHASE1
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: Contrast-Enhanced Ultrasound — Undergo CEUS
  • Drug: Perflutren Lipid Microspheres — Given IV
  • Drug: Sulfur Hexafluoride Lipid Microspheres — Given IV

Primary Outcomes

  • Radiomics-based ML-classifier framework (Up to 12 months)
  • Performance of radiomics-based ML approach to prevent unnecessary biopsies (Up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2020-11-05
Completion: 2027-11-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Bino A Varghese, PhD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Janet Jaime
323-865-3205
Janet.jaime@med.usc.edu
Janet Jaime
323-865-3205
Janet.Jaime@med.usc.edu
Los Angeles County-USC Medical Center
Bino A. Varghese, PhD
Los Angeles County-USC Medical Center
Interventions
  • Procedure: Contrast-Enhanced Ultrasound — Undergo CEUS
  • Drug: Perflutren Lipid Microspheres — Given IV
  • Drug: Sulfur Hexafluoride Lipid Microspheres — Given IV
Study Locations (2 sites)
Los Angeles County-USC Medical Center, Los Angeles, California 90033 United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed breast masses assigned as BIRADS 4a, 4b, 4c or 5 by conventional US and recommended for ultrasound guided biopsy * Age \>= 18 years * Female Exclusion Criteria: * Contraindications to microbubble contrast: Patients who have a known pulmonary hypertension and any known hypersensitivity to US contrast agent * Women with renal failure or insufficiency (only if patient is receiving CESM scan) * Women with Iodine contrast allergy (only if patient is receiving CESM scan) * Women with the largest side of the mass measuring ≤ 1 cm (only if patient is receiving CEUS scan) * Women who are pregnant, possibly pregnant, or lactating * Women currently undergoing neoadjuvant chemotherapy * Women \< 18 years of age * Patient ≤ 30 years (only if patient is receiving CESM scan) * Masses in the same breast that had prior lumpectomy for cancer * Women with cancer in the same breast will be excluded however, women with cancer in the contralateral breast will be eligible to participate in the study * Women with an allergy to perflutren (only if patient is receiving CEUS scan) * Prior history of biopsy for that specific lesion * Women with breast implants
Conditions HER2-positive Breast Cancer, Advanced Br...
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib + Trastuzumab. The aim is to explore the efficacy and safety of Pyrotinib, Trastuzumab, and Taxanes in treating Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib — Pyrotinib 400mg qd po continuously
  • Drug: Trastuzumab — For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
  • Drug: Taxanes — Taxanes: Usual clinical dose is administered, in a 21-day cycle.
  • Drug: Capecitabine — Capecitabine: 650mg/m2 each time, given twice daily

Primary Outcomes

  • PFS (24months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-01-02
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hebei Medical University Fourth Hospital
Contact Information
Study Contact:
Lina zhang
18531117825
linazh_001@163.com
The Fourth Hospital of Hebei Medical University
Interventions
  • Drug: Pyrotinib — Pyrotinib 400mg qd po continuously
  • Drug: Trastuzumab — For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
  • Drug: Taxanes — Taxanes: Usual clinical dose is administered, in a 21-day cycle.
  • Drug: Capecitabine — Capecitabine: 650mg/m2 each time, given twice daily
Study Locations (1 sites)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000 China
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-70 years old, female; 2. Pathological examination confirmed HER-2 positive invasive breast cancer; (HER2 positivity is defined as an immunohistochemical (IHC) score of 3+ or in-situ hybridization (ISH) result for HER2 gene amplification in \>10% of immunoreactive cells. HER2 positivity needs to be verified by the pathology department of the research center involved in this study) 3. Imaging confirmed recurrent/metastatic breast cancer; 4. Patients who relapsed and metastasized three months after discontinuation of Trastuzumab treatment; 5. Have at least one measurable lesion (according to RECIST 1.1 criteria); 6. ECOG score of 0-2; 7. Expected life span ≥3 months; 8. Normal major organ function; 9. The researcher believes that the participant may benefit; 10. Volunteer to participate in this study, sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria are not eligible for participation: 1. Have any confirmed history of drug allergies, or severe allergic reactions to any component of the investigational drug (NCI-CTCAE 5.0 grade \> 3); 2. Patients in advanced stages who have undergone systemic treatment; 3. A history of serious heart diseases such as congestive heart failure, unstable angina, arrhythmia or myocardial infarction; 4. Suffer from serious pulmonary diseases, such as interstitial lung disease or pneumonia, pulmonary fibrosis, acute pulmonary diseases, etc.; 5. Currently suffering from severe liver-related diseases, such as acute hepatitis, explosive hepatitis, coagulation factor synthesis disorder, etc.; Those who are positive for HBV surface antigen or HBV core antibody must have a peripheral blood Hepatitis B virus DNA titer test \< 1×10 \^3 IU/ml in order to participate; 6. Comorbidity or condition that may interfere with their participation in the study, or any serious medical impediment that might affect participant's safety (such as, active or uncontrolled infection, active liver/gallbladder disease requiring antiviral treatment); 7. Other invasive tumors (including second primary breast cancer) that may affect the evaluation of results and adherence to the protocol; 8. Having undergone major surgical procedure or are yet to recover from major internal diseases within the 4 weeks prior to the study; 9. Any circumstance that the researcher considers the participant unfit to participate in the study.

Better Sleep Study

NCT06139861
Recruiting
Conditions Depression in Adolescence, Delayed Sleep...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of this proposal is a confirmatory efficacy trial sufficiently powered and designed to test the hypothesis that improving the relationship between biological circadian timing and waketime, a novel modifiable target, improves depression outcomes in a subgroup of adolescents with depression and a misaligned relationship between biological circadian timing and waketime utilizing a cognitive-behavioral sleep intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: TranS-C — Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
  • Behavioral: Psychoeducation — The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.

Primary Outcomes

  • Change in phase angle difference (PAD) between DLMO and waketime (PADDLMO WAKETIME ) (baseline to end of treatment (0 and 2 months))
  • Change in Children's Depression Rating Scale (CDRS-R) (baseline to end of treatment (anticipated average exposure 2 months), months 8 and 14)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-15
Completion: 2028-08-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Los Angeles
Collaborators: Stanford University, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Lauren M Asarnow, PhD (PRINCIPAL_INVESTIGATOR) - Children's Hospital Los Angeles
Contact Information
Study Contact:
Lauren Asarnow, PhD
323-361-2471
lasarnow@chla.usc.edu
Lauren Asarnow, PhD
323-361-2471
lasarnow@chla.usc.edu
Children's Hospital Los Angeles
Lauren Asarnow, PhD
Children's Hospital Los Angeles
Interventions
  • Behavioral: TranS-C — Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
  • Behavioral: Psychoeducation — The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
Study Locations (1 sites)
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Eligibility Criteria
Inclusion Criteria: Exclusion Criteria: * mental health/behavioral symptoms that would preclude productive engagement in study assessments or intervention (e.g., active psychosis; Bipolar Disorder; drug dependence * severe or unstable medical or psychiatric condition such that treatment has changed within the last month or is expected to change during the course of the study or that would preclude ability to adhere to study procedures (e.g. terminal end-stage cancer) * current use of medications or herbs with known effects on sleep * plan to undergo or have had medication change in the last 8 weeks
Conditions Advanced or Metastatic Solid Tumor
Phase PHASE1
Enrollment 124
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PLN-101095 — PLN-101095 250 mg BID
  • Drug: PLN-101095 — PLN-101095 500 mg BID
  • Drug: PLN-101095 — PLN-101095 1000 mg BID
  • Drug: PLN-101095 — PLN-101095 1000 mg TID
  • Drug: PLN-101095 — PLN-101095 2000 mg BID
  • Drug: PLN-101095 — PLN-101095
  • Drug: Pembrolizumab — Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Primary Outcomes

  • Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2 (First dose to 35 days)
  • Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2 (Day 1 until 16 weeks after end of study treatment regimen)
  • Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2 (First dose to disease progression or death from any cause, whichever occurs first.)
  • Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2 (First dose to disease progression or death from any cause, whichever occurs first.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-08-30
Completion: 2030-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pliant Therapeutics, Inc.
Principal Investigators:
  • Pliant Therapeutics Medical Monitor (STUDY_DIRECTOR) - Pliant Therapeutics, Inc.
Contact Information
Study Contact:
Pliant Therapeutics Medical Monitor
clintrials@pliantrx.com
clintrials@pliantrx.com
Pliant Therapeutics Medical Monitor
clintrials@pliantrx.com
Winship Cancer Institute of Emory University
Pliant Therapeutics Medical Monitor
clintrials@pliantrx.com
South Texas Accelerated Research Therapeutics (START)
Interventions
  • Drug: PLN-101095 — PLN-101095 250 mg BID
  • Drug: PLN-101095 — PLN-101095 500 mg BID
  • Drug: PLN-101095 — PLN-101095 1000 mg BID
  • Drug: PLN-101095 — PLN-101095 1000 mg TID
  • Drug: PLN-101095 — PLN-101095 2000 mg BID
Study Locations (12 sites)
Yale University, New Haven, Connecticut 06511 United States
Winship Cancer Institute of Emory University, Atlanta, Georgia 30322 United States
South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan 49546 United States
START New Jersey, East Brunswick, New Jersey 08816 United States
START New York Long Island LLC, Lake Success, New York 11042 United States
Carolina Cancer Research Center, Wilson, North Carolina 27893 United States
NEXT Austin, Austin, Texas 78758 United States
START Center for Clinical Research, Fort Worth, Texas 76104 United States
University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
NEXT Houston, Houston, Texas 77054 United States
Eligibility Criteria
Inclusion Criteria: 1. Has histologically or cytologically confirmed advanced or metastatic solid tumor 2. Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies 3. Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only) 4. Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment 5. At least 1 measurable lesion, as defined by RECIST v1.1 6. Estimated survival of ≥3 months 7. Have adequate bone marrow and organ function. 8. A female participant is eligible to participate if she is not pregnant, not breastfeeding Exclusion Criteria: 1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab 2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years 3. Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy 4. Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications 5. Has a diagnosis of immunodeficiency or use of systemic steroids \>10 mg/day 6. Has an active autoimmune disease that has required systemic treatment in the past 2 years 7. Has known active CNS metastases (brain and/or leptomeningeal metastases) 8. Has significant cardiac disease 9. Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C) 10. Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Conditions Obesity, Type 2 Diabetes Mellitus, Baria...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Using radiomics of intra-abdominal and subcutaneous adipose tissue and clinical features to predict the weight loss efficacy and remission of type 2 diabetes mellitus after bariatric surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Area under curve (AUC) of the weight loss prediction model after 1 year (1 year)
  • Area under curve (AUC) of the T2DM remission prediction model after 1 year (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2027-12-31
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China-Japan Friendship Hospital
Principal Investigators:
  • Yuntao Nie, M.D. (PRINCIPAL_INVESTIGATOR) - China-Japan Friendship Hospital
Contact Information
Study Contact:
Yuntao Nie, M.D.
+8618611835860
nytnyt1231@163.com
Hua Meng, M.D.
+8618611457779
menghuade@hotmail.com
Yuntao Nie, M.D.
+8618611835860
nytnyt1231@163.com
Yuntao Nie
Interventions
N/A
Study Locations (1 sites)
Yuntao Nie, Beijing, 100029 China
Eligibility Criteria
Inclusion Criteria: * BMI\>27.5kg/m2; Type 2 diabetes mellitus; Patients who will undergo bariatric surgery Exclusion Criteria: * Patients without abdominal CT scan; Patients did not undergo sleeve gastrectomy or Roux-en-Y gastric bypass.
Conditions Diagnosis, Asthma
Phase NA
Enrollment 171
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Global Initiative of Asthma Guideline (GINA) recommends a flowchart to diagnose asthma with first-step spirometry with reversibility and a bronchial challenge test (BPT) with histamine or methacholine as a second step. This multi-center prospective care evaluation study compares the 'standard asthma diagnostic work-up' (spirometry with reversibility and BPT) to the 'new asthma diagnostics work-up' (FeNO-test as an intermediate step between the spirometry with reversibility and the BPT), intending to determine the impact of the FeNO-based strategy, in terms of the number of avoided BPTs, cost-effectiveness and reduced burden to the patient and health care. The cost reduction of incorporating the FeNO-test in the new diagnostic algorithm will be established by the number of theoretically avoided BPT. The decrease in burden will be studied by calculating differences in the Visual Analogue Scale (VAS) -score and Asthma Quality of Life Questionnaire (AQLQ) -score after the BPT and FeNO-test with an independent T-test. The accuracy of the FeNO-test will be calculated by comparing the FeNO-test outcomes to the (gold standard) BPTs outcomes in terms of sensitivity and specificity.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: FeNO-test — Fractional Exhaled Nitric Oxide (FeNO)- test

Primary Outcomes

  • Number of provocation tests per year (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-01
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 171 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Franciscus Gasthuis & Vlietland (Hospital)
Collaborators: OLVG
Contact Information
Study Contact:
Hanna Kuiper-van der Valk, Dr
+31642192700
h.kuiperv-andervalk@franciscus.nl
Gert-Jan Braunstahl, Dr
G.J.Braunstahl@franciscus.nl
Interventions
  • Diagnostic Test: FeNO-test — Fractional Exhaled Nitric Oxide (FeNO)- test
Study Locations (1 sites)
Hanna Kuiper-van der Valk, Rotterdam, South Holland 3045PM Netherlands
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years old visiting the outpatient clinic pulmonology with the suspicion of asthma will be asked to participate in this study. For reasons of external validity and generalizability of the study results, it was decided not to exclude subgroups such as smokers or obese patients. Exclusion Criteria: * Patients with already diagnosed asthma are not allowed to participate. * The inclusion of patients with respiratory infections \<3 weeks ago will be postponed to \>3 weeks.